Shionogi Receives $119M BARDA Award to Establish US Antibiotic Manufacturing Plant

on

Shionogi received an initial $119 million award from BARDA under its Project BioShield program to establish a US antibiotic manufacturing plant12

BARDA could purchase up to $482 million of Fetroja under the program1

Fetroja treats infections caused by Gram-negative pathogens including pneumonia and urinary tract infections1

Fetroja first received US regulatory approval in 2019 for complicated urinary tract infections3

Shionogi is joining multiple drugmakers in announcing US manufacturing commitments2

Sources:

1. https://insights.citeline.com/scrip/therapeutic-category/

2. https://news.pda.org

3. https://www.fiercepharma.com/manufacturing/shionogi-nabs-initial-119m-barda-build-us-antibiotic-plant